drugset / Trial / NCT00236145
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a successful dose of ACTIQ treatment more quickly. The successful ACTIQ dose provides a satisfactory combination of efficacy and tolerability after a single administration, as assessed by the patient.
Timeline
- Start
- 2004-06
- Primary completion
- 2005-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fentanyl | Other / unclassified | — | Oral |
Indications
No indication recorded.